ELOX stock: Eloxx reports 5.5 million US dollar quarterly loss
Published on 11/19/2026 at 03:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSClinical programs advance after quarterly update
- Eloxx has dosed the first two patients in its Phase 2b EXACT study for nonsense mutation Alport syndrome.
- The company expects first dosing in the EXPRESS study for nonsense mutation ADPKD in the third quarter of 2027.
- Eloxx reported cash and cash equivalents of 56.3 million US dollars at September 30, 2026.
Eloxx Pharmaceuticals reported third-quarter results on Monday, November 16, 2026, alongside an update on its exaluren pipeline. The clinical-stage biopharmaceutical company posted a net loss of 5.5 million US dollars for the quarter ended September 30, compared with a loss of 0.4 million US dollars a year earlier, according to PR Newswire.
Loss widens as trial spending rises
Research and development expenses reached 4.0 million US dollars, compared with a net credit of 0.3 million US dollars in the year-earlier quarter. Eloxx said the increase reflected higher clinical-trial and personnel costs, while prior-year expenses benefited from vendor settlements. General and administrative expenses rose to 1.9 million US dollars from 0.5 million US dollars.
Loss per share narrowed to 0.49 US dollars from 0.58 US dollars. The company held 56.3 million US dollars in cash and cash equivalents at September 30, down from 62.0 million US dollars at June 30, and said the balance should fund operations into 2028.
Two kidney studies set milestones
Eloxx said the first two patients were dosed in September in the global Phase 2b EXACT study of exaluren for nonsense mutation Alport syndrome. The trial is designed to enroll 24 patients, with topline results from its initial 16-week placebo-controlled portion expected in mid-2027 and final 32-week data due by the end of 2027.
The company has also finalized the 52-week EXPRESS study for approximately 60 adults with nonsense mutation autosomal dominant polycystic kidney disease. The US Food and Drug Administration cleared the relevant investigational new drug application in October, and Eloxx expects to dose the first patient in the third quarter of 2027, with topline data expected in the first half of 2029.
Eloxx focuses on rare genetic disease
Eloxx Pharmaceuticals is a US clinical-stage biopharmaceutical company developing small-molecule candidates that modulate the ribosome and promote readthrough of premature stop codons. Its lead candidate, exaluren, targets rare kidney diseases including nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease. The company has also exclusively licensed ZKN-013 to Almirall for rare dermatological diseases linked to nonsense mutations.
Eloxx Pharmaceuticals at a glance
- Company: Eloxx Pharmaceuticals, Inc.
- Ticker: ELOX
- Home exchange: Nasdaq
- Reporting period: Third quarter ended September 30, 2026
- Cash and cash equivalents: 56.3 million US dollars as of September 30, 2026
The US biotechnology sector remains the broader market setting for Eloxx, alongside the S&P 500.
